Kurse werden geladen...
Prognose
Kaufen | 2 |
Halten | 2 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Senti Bio Participates in Nasdaq Amplify Spotlight Series
Access the segment here» Mehr auf globenewswire.com
Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference
SOUTH SAN FRANCISCO, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference being held June 23-26, 2025 in Houston, TX.» Mehr auf globenewswire.com
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year 1 with 60% of patients experiencing relapse or death within 12 months 2 Management releases Virtual Investor “What This Means” segment; Access here SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML.» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −13,04 Mio | 16,24% |
EBITDA | −15,16 Mio | 10,23% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 48,71 Mio€ |
Anzahl Aktien | 26,08 Mio |
52 Wochen-Hoch/Tief | 14,38€ - 1,29€ |
Dividenden | Nein |
Beta | 2,24 |
KGV (PE Ratio) | −0,40 |
KGWV (PEG Ratio) | −0,04 |
KBV (PB Ratio) | 0,58 |
KUV (PS Ratio) | 9,80 |
Unternehmensprofil
Name | Senti Biosciences Inc. |
CEO | Timothy K. Lu |
Mitarbeiter | 34 |
Assets entdecken
Shareholder von Senti Biosciences Inc. investieren auch in folgende Assets